We think differently about mental health so you can too
Our vision is a world of mental wellbeing.
COMPASS is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first programme is researching how investigational COMP360 psilocybin treatment (also known as psilocybin therapy) could help people with treatment-resistant depression.
We want to transform the patient experience in mental health care.

Our team
Everyone has a mental health story, be it their own, or that of a friend or loved one. Our people bring their stories, and a wide range of backgrounds and skills to COMPASS.
Our research
Our research is evidence-based and underpinned by a commitment to find better ways to support and empower people suffering with poor mental health.
News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology, and digital platforms.
-
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors
-
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
-
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin